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Background: PA28γ was suggested to play a role in malignant progression. This paper aimed to investigate the
association between PA28γ and the prognosis of oral squamous cell carcinoma (OSCC) in cohort studies.
Methods: The PA28γ expression level was assessed by immunohistochemistry in a total of 368 OSCC patients
from three independent cohorts. The Cox proportional hazards regression model was used to determine multi-
variate hazard ratios for Overall Survival (OS).Model discriminationwasmeasured using C Statistic. Additionally,
OS was analyzed in Head Neck Squamous Cell Carcinoma (HNSCC) patients from The Cancer Genome Atlas
(TCGA) data set. Functional analyses were conducted both in-vitro and in-vivo.
Findings: The median follow-up times of patients in the three studies were 60, 52, and 51 months. High expres-
sion of PA28γ was identiﬁed in tumors from 179 of 368 patients (48.6%). Compared with low expression, high
expression of PA28γ was strongly associated with worse OS, with relative risks of 5.14 (95% CI, 2.51–10.5;
P b 0.001), 2.82 (95% CI, 1.73–4.61; P b 0.001), and 3.85 (95% CI, 1.59–9.37; P = 0.003). PA28γ expression
was also associated with disease-free survival in all three cohorts (P b 0.005). These ﬁndings are consistent
with TCGA HNSCC data (P b 0.006). The prediction of all-cause mortality was signiﬁcantly improved when
PA28γ was added to the traditional clinical factors (Model 3, C statistic value: 0.78 VS 0.73, P = 0.016). In
functional analyses, we found that PA28γ silencing dramatically inhibited the growth, proliferation and
mobility of OSCC cells in vitro and reduced tumor growth and angiogenesis in tumor-bearing mice.
Interpretation: PA28γ overexpression is associated with adverse prognosis in patients with OSCC. The aber-
rant expression of PA28γ may contribute to the pathogenesis and progression of OSCC.
Research in context: OSCC is one of the most common HNSCC, which have a high lethally rate. However, few
prognostic markers have been applied in the clinical practice. We found that PA28γ in OSCC tumor tissues
were signiﬁcantly high expression than those in normal tissues. As the results of the three cohorts from two
independent research centers and from an additional validation cohort from a US population in the TCGA
dataset, we demonstrate PA28γ is a good predictor of the risk of death in OSCC. Meanwhile, we demonstrate
PA28γ have a potential role in OSCC tumorigenesis.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).l Diseases, West China Hospital
innan Road, Chengdu, Sichuan
g), zengxin22@163.com
. This is an open access article under1. Introduction
OSCC is one of themost commonHNSCC, with an estimated 260,000
new cases and 120,000 deaths worldwide each year (Jemal et al., 2011).
Despite recent advances in diagnosis and treatment, the 5-year survival
rate of patients with OSCC is no more than 50% (Panzarella et al., 2014).
Over the past two decades, numerous prognostic and predictive
markers for clinical outcomes in OSCC have been proposed (Ratajczak-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
852 J. Li et al. / EBioMedicine 2 (2015) 851–858Wrona et al., 2013); however, few have been applied in clinical practice
due to the non-reproducibility of the initial ﬁndings (Choi and Myers,
2008; Principe et al., 2013). To date, the classical clinic pathological pa-
rameters of tumor such as primary site, tumor stage, lymph nodal stage
and clinical TNM stage remain the most signiﬁcant factors to affect out-
come of patients with OSCC. However, it is impossible to predict pa-
tients at a high risk of death mainly based on these parameters.
Therefore, it is critical to identify novel and effective prognostic predic-
tors and therapeutic targets for treating this common malignancy.
In eukaryotic cells, proteasomes play an essential role in intracellular
proteolysis and are involved in the control of most biological processes
through regulated degradation of key proteins. PA28 is a member of a
unique family of proteasomal activators that has the ability to stimulate
the proteolytic activity of the 20S core proteasome independent of
ubiquitination and ATP (Li et al., 2007). Unlike PA28α and PA28β,
PA28γ (also known as Ki antigen, 11Sγ, or REGγ) localizes in the nucle-
us and forms a homo-heptamer (Kloetzel and Ossendorp, 2004;
Rechsteiner et al., 2000; Rivett and Hearn, 2004). PA28γ, regulated by
MEKK3, B-RAF, caspase-3/7 and targeted by miR-7-5p, is a multifunc-
tional protein that is involved in the degradation of important regulato-
ry proteins, such as SRC-3, PTTG1 and cyclin-dependent kinase
inhibitors p21/16/19 in an ubiquitin- and ATP-independent manner,
and has been implicated in the regulation of cell cycle progression (Li
et al., 2007; Araya et al., 2002; Chen et al., 2007; Ying et al., 2006; Shi
et al., 2015). Moreover, PA28γ-deﬁcient mice have been shown to ex-
hibit growth retardation (Barton et al., 2004). Several targets of PA28γ
have been identiﬁed in recent years, suggesting that it plays important
roles in angiogenesis, hepatic lipid metabolism, infectious diseases and
premature aging (Liu et al., 2014; Dong et al., 2013; Yan et al., 2014; Li
et al., 2013). PA28γ is over-expressed in some cancer tissues, suggesting
that this protein may also have a potential role in tumorigenesis (Wang
et al., 2011; Roessler et al., 2006). Some studies found that PA28γmay
facilitate the turnover of the tumor suppressor p53 by promoting mu-
rine double minute 2 (MDM2)-mediated p53 ubiquitination (He et al.,
2012; Zhang and Zhang, 2008) and PA28γ could take part in the ATM-
DBC1-SIRT1 axis induced p53-dependent apoptosis (Magni et al.,Fig. 1. Study ﬂ2014). Recently researchers found that mutant p53 (p53-R248Q)
could up-regulate PA28γ in endometrial cancer (Wang et al., 2015),
thus, there is an auto-regulatory feedback loop between p53 and
PA28γ (Wan et al., 2014). Nevertheless, the mechanism by which
PA28γ exerts its effects on tumor cells remains unclear.
In our previous study, we conducted a comprehensive proteomic
analysis to identify candidate biomarkers in OSCC (Wang et al., 2008).
Expression levels of 52 proteins in OSCC tumor tissues were signiﬁcant-
ly different from those in normal tissues (Wang et al., 2009). One of
these proteins was PA28γ. The bioprocesses and interaction network
analysis indicated that PA28γmight play an important role inmalignant
transformation. Given these ﬁndings, we hypothesized that PA28γmay
be involved in malignant development and progression of OSCC and
would have effect on the prognosis of this disease. To test this hypothe-
sis, we ﬁrst explored the protein expression proﬁle of PA28γ and its re-
lationswith the outcome of OSCC patients in three independent cohorts
from two centers. Then, we constructed models to predict death of pa-
tients with OSCC using PA28γ individually and jointly with other prog-
nostic factors identiﬁed in these three cohorts. Finally, we investigated
the effects of PA28γ on the biological behavior of OSCC cells both
in vitro and in vivo.
2. Methods and patients
2.1. Patients
The Institutional Review Boards of the West China Hospital of
Stomatology, Sichuan University and Guangdong Provincial
Stomatological Hospital approved this study. The study was approved
by the ethics committee both of the West China Hospital of Stomatology
and the Guangdong Provincial Stomatological Hospital and was conduct-
ed in agreementwith the Helsinki Declaration.Written informed consent
was provided by all participants at baseline and during follow-up.
A total of 368 postoperative patients with primary OSCC tumors re-
ceived regular follow-up. Follow-upvisits entailed at least amedical his-
tory and clinical examination. In addition to scheduled visits, all patientsow chart.
Table 1








Number (%) Number (%) Number (%)
Age–yr (mean ± sd) 58.97 ± 13.67 58.76 ± 10.62 60.39 ± 12.35 0.563
b60 yr 55 (46.61) 76 (48.72) 42 (44.68) 0.821
≥60 yr 63 (53.39) 80 (51.28) 52 (55.32)
Sex
Male 81 (68.64) 112 (71.79) 55 (58.51) 0.089
Female 37 (31.36) 44 (28.21) 39 (41.49)
Smoking
Never 65 (55.08) 76 (48.72) 50 (53.19) 0.556
Ever 53 (44.92) 80 (51.28) 44 (46.81)
Drinking
Never 62 (52.54) 76 (48.72) 55 (58.51) 0.324
Ever 56 (47.46) 80 (51.28) 39 (41.49)
Differentiation
High 75 (63.56) 104 (66.67) 72 (76.60) 0.144
Moderate 37 (31.36) 40 (25.64) 20 (21.28)




50 (42.37) 71 (45.51) 54 (57.45) b0.001
Buccal mucosa 18 (15.25) 27 (17.31) 10 (10.64)
Gingiva 15 (12.71) 23 (14.74) 25 (26.60)
Othersa 35 (29.66) 35 (22.44) 5 (5.32)
Tumor stage
T1 36 (30.51) 34 (21.79) 19 (20.21) b0.001
T2 61 (51.69) 48 (30.77) 48 (51.06)
T3 15 (12.71) 53 (33.97) 12 (12.77)
T4 6 (5.08) 21 (13.46) 15 (15.96)
Nodal stage
N0 82 (69.49) 108 (69.23) 71 (75.53) 0.522
N1–N3 36 (30.51) 48 (30.77) 23 (24.47)
Clinical TNM stage
I 28 (23.73) 29 (18.59) 15 (15.93) 0.009
II 45 (38.14) 37 (23.72) 38 (40.43)
III 24 (20.34) 57 (36.54) 20 (21.28)
IV 21 (17.80) 33 (21.15) 21 (22.34)
Surgery type
Local 49 (41.53) 55 (35.26) 18 (19.15) b0.001
Unilateral neck 62 (52.54) 82 (52.56) 65 (69.15)
Bilateral neck 6 (5.08) 4 (2.56) 6 (5.32)
Other 1 (0.85) 15 (9.62) 5 (5.32)
Radiotherapy
Yes 9 (7.63) 28 (17.95) 15 (15.96) 0.044
No 109 (92.37) 128 (82.05) 79 (84.04)
Chemotherapy
Yes 65 (55.08) 84 (53.85) 42 (44.68) 0.262
No 53 (44.92) 72 (46.15) 52 (55.32)
Radiotherapy or
chemotherapy
Yes 67 (56.78) 93 (59.62) 49 (52.13) 0.512
No 51 (43.22) 63 (40.38) 45 (47.87)
PA28γ
Low expression 56 (47.46) 96 (61.54) 37 (39.36) 0.002
High expression 62 (52.54) 60 (38.46) 57 (60.64)
Abbreviations: CD, Chengdu; GZ, Guangzhou.
⁎ P value of comparison between studies was generated using mixed linear model for
continuous variables and chi-square test or Fisher's exact test for categorical variables.
a Others included hard palate, mandibular and lip mucosa.
853J. Li et al. / EBioMedicine 2 (2015) 851–858could initiate visits if theywere concerned that they had recurrence or a
new primary tumor. The survival time of each patient was calculated
from the day of surgery until the time of cancer-related death or the
end of the follow-up period, death for other reasons led to censoring
of data. The detailed information of three cohorts was described in Sup-
plemental Patients and Methods.
An independent cohort of 460 patient specimens obtained between
1992 and 2013 in the TCGA database (http://tcga-data.nci.nih.gov/tcga/
) was used as an external validation cohort to validate the prognostic
value of PA28γ in patients with HNSCC (Table S1).
2.2. Laboratory experiments
All animal studies were approved by the Animal Care and Use Com-
mittee, State Key Laboratory of Oral Diseases, in compliance with the
Guide for the U.S. Public Health Service's policy on humane care and
use of laboratory animals (Kilkenny et al., 2010). Animals were housed
within 12-h light/dark cycles and received food, standard rodent chow,
andwater ad libitum in compliancewith the Association for Assessment
and Accreditation of Laboratory Animal Care International guidelines.
Other methods are detailed in Supplemental Patients and Methods in-
cluding Cell Culture and siRNA transfections, western blot analysis,
MTT, colony-formation, propidium iodide (PI) staining, ﬂow cytometry,
TUNEL, cell invasion, cell migration, in vivo tumor-formation assay, and
immunohistochemistry.
2.3. Statistical analysis
Baseline characteristics among the patients were compared using
the mixed linear model for continuous variables and the χ2 test or
Fisher's Exact Test for categorical variables. OS and DFS were estimated
using the Kaplan–Meier method, with a log-rank test in a univariate
analysis. Multivariate survival analysis was done using the Cox propor-
tional hazards model. Model discrimination was measured using C
Statistic for survival analysis. Receiver operating characteristic (ROC)
curve area was used in the prediction model.
Statistical analyses were performed using SAS software, version 9.3
(SAS Institute Inc., Cary, NC). Unless stated otherwise, two-sided
P b 0.05were considered signiﬁcant. Details on data analysis are provid-
ed in the Supplementary.
3. Results
3.1. Patient and disease characteristics
A total of 368 patients from three independent cohorts (118, 156,
and 94patients in CD-I cohort, CD-II cohort, andGZ cohort, respectively)
were included in this study (Fig. 1). All patients were treatedwith cura-
tive intent. Some of these patients had been treated by radiotherapy
and/or chemotherapy. The mean age and gender distribution were
comparable across the three cohorts. The median durations of follow-
up in the cohorts were 60, 52, and 51months, respectively. IHC staining
showed that PA28γ has a very clear nuclear positive in most tumor but
not normal tissues (Fig. S1). High expression of PA28γwas observed on
OSCC cell lines, and in 52.54%, 38.46%, and 60.64% of the patients in the
CD-I cohort, CD-II cohort and GZ cohort, respectively (Table 1 and
Fig. S2). This ﬁnding is consistent with the TCGA database analysis of
PA28γmRNA abundance in human primary oral cancers (Fig. S3a).
3.2. Univariate and multivariate analyses of PA28γ expression and its
predictive value
In all three cohorts, the results of univariate analysis showed that OS
at ﬁve years was associated with PA28γ expression (Table 2). For the
CD-I cohort, estimated 5-year OS values for patients in the low and
high PA28γ expression groups were 84% (95% CI, 0.71–0.91) and 40%(95% CI, 0.28–0.52; Fig. 2a), respectively. For the CD-II cohort, the esti-
mated 5-year OS values for patients in the low and high PA28γ expres-
sion groups were 67% (95% CI, 0.56–0.57) and 28% (95% CI, 0.18–0.40;
Fig. 2b), respectively. For the joint CD-I and CD-II cohorts, the estimated
5-year OS for patients also showed that the risk increased associated
with positive staining (P b 0.001; Fig. 2c). For the GD validation cohort,
the estimated 5-year OS values for patients in the low and high PA28γ
expression groups were 89% (95% CI, 0.74–0.96) and 57% (95% CI,
0.43–0.69; Fig. 2d), respectively. Consistent with an external validation
cohort of 460HNSCC patients from the TCGA database analysis in theUS
population, high PA28γmRNA was associated with poor survival (P=
0.016, Fig. S3b). Furthermore, the association between PA28γ high
854 J. Li et al. / EBioMedicine 2 (2015) 851–858expression with lower rates of 5-year Disease-Free Survival (DFS) was
also statistically signiﬁcant in those three independent cohorts (P b
0.001; CD-II: P b 0.001; joint CD-I and -II cohorts: P b 0.001; GD: P =
0.004; Table S2; Fig. S4). Several conventional prognostic factors, in-
cluding lower cell differentiation, positive nodal stage, higher tumor
stage, higher clinical TNM stage and radiotherapy or chemotherapy,
were associated with a signiﬁcantly increased risk of death. History of
smoking and alcohol consumption were signiﬁcantly related with sur-
vival (P b 0.005). Some of these factors were included in the multivari-
able Cox proportional-hazards model and ﬁxed.
Results of the predictive analysis are provided in Table 3. Strong
PA28γ expression was independently associated with signiﬁcantly re-
duced OSCC patients' OS in the CD-I cohort (HR, 5.14; 95% CI, 2.51–
10.5; P b 0.001) after accounting for smoking history, drinking history,
cell differentiation, tumor stage, nodal stage and radiotherapy or che-
motherapy; this was later conﬁrmed in the CD-II cohort (HR, 2.82;
95% CI, 1.73–4.61; P b 0.001). There is evidence that patients with
PA28γ high expression had worse DFS in the CD-I and CD-II cohorts,
with hazard ratios of 3.82 (95% CI, 2.12–6.88; P b 0.001) and 2.96 (95%
CI, 1.87–4.69; P b 0.001), respectively (Table S3), after accounting forTable 2
Univariate analyses of selected characteristics with survival among patients with oral squamou
Characteristic CD-I cohort (N = 118)
OS at ﬁve years P value⁎
(95% CI)
Age
b60 yr 0.65 (0.51–0.76) 0.510
≥60 yr 0.56 (0.43–0.68)
Sex
Male 0.58 (0.46–0.67) 0.327
Female 0.68 (0.50–0.80)
Smoking history
Never 0.75 (0.63–0.84) b0.001
Ever 0.43 (0.30–0.56)
Drinking history
Never 0.69 (0.56–0.79) 0.037
Ever 0.52 (0.38–0.64)
Cell differentiation
High 0.70 (0.58–0.79) 0.003
Moderate or Low 0.44 (0.29–0.58)
Primary site
Ventral tongue/ﬂoor of mouth 0.59 (0.44–0.72) 0.814




T1 or T2 0.66 (0.55–0.74) 0.003
T3 or T4 0.33 (0.15–0.53)
Nodal stage
N0 0.72 (0.60–0.80) b0.001
N1-N3 0.36 (0.21–0.51)
Clinical TNM stage
I or II 0.76 (0.65–0.85) b0.001
III or IV 0.36 (0.22–0.49)
Surgical method
Local 0.61 (0.46–0.73) 0.878
Unilateral or bilateral or other 0.60 (0.48–0.71)
Radiotherapy
Yes 0.78 (0.36–0.94) 0.347
No 0.59 (0.48–0.68)
Chemotherapy
Yes 0.74 (0.61–0.83) 0.002
No 0.44 (0.31–0.57)
Radiotherapy or chemotherapy
Yes 0.75 (0.62–0.83) b0.001
No 0.42 (0.28–0.55)
PA28γ
Low expression 0.84 (0.71–0.91) b0.001
High expression 0.40 (0.28–0.52)
Abbreviations: OS, Overall Survival; CD, Chengdu; GZ, Guangzhou.
⁎ P value was determined using the log-rank test.
a Others included hard palate, mandibular and lip mucosa.the same factors as in the OS analysis. Furthermore, in the joint CD-I
and CD-II cohorts and in the validation GZ cohort, the analysis results
showed similar patterns (P b 0.001; Table 3; Table S3).
3.3. Prediction models for all-cause death of OSCC patients
Multivariable models were constructed for the prediction of all-
cause death in OSCC patients by using the combined CD cohort as the
discovery cohort, and the GD cohort as a validation cohort. We assessed
model discrimination using the C statistic for predictive value and com-
pared the difference betweenbasicmodels andmodels including PA28γ
expression (Table S4). For thediscovery of CD cohort, inModel 1, among
the basic risk factors, the C statistic value of PA28γ was highest. The C
statistic increased signiﬁcantly when PA28γ was combined with those
conventional risk factors in Models 2 to 4. In Models 3 and 4, when
PA28γ was added, the C statistic was larger than 0.75, above which
the prediction model is considered relatively good. Similar results
were found in the validation GZ cohort. ROC curves were constructed
for themodeModels 3 and 4, in which the area under the ROC curve in-
dicates the C statistic (Figs. 3, S5).s cell carcinoma.
CD-II cohort (N = 156) GZ cohort (N = 94)
OS at ﬁve years P value⁎ OS at ﬁve years P Value⁎
(95% CI) (95% CI)
0.47 (0.36–0.58) 0.139 0.81 (0.66–0.90) 0.057
0.56 (0.45–0.66) 0.61 (0.46–0.73)
0.54 (0.45–0.63) 0.422 0.67 (0.52–0.78) 0.352
0.45 (0.30–0.59) 0.74 (0.58–0.85)
0.58 (0.46–0.68) 0.108 0.75 (0.60–0.85) 0.097
0.46 (0.35–0.57) 0.64 (0.48–0.76)
0.65 (0.54–0.75) b0.001 0.78 (0.65–0.87) 0.027
0.39 (0.28–0.49) 0.58 (0.41–0.72)
0.58 (0.48–0.66) 0.020 0.75 (0.63–0.83) 0.042
0.40 (0.27–0.53) 0.55 (0.32–0.72)
0.56 (0.44–0.67) 0.477 0.72 (0.58–0.82) 0.265
0.44 (0.25–0.62) 0.86 (0.33–0.98)
0.43 (0.23–0.62) 0.50 (0.25–0.71)
0.54 (0.37–0.69) 0.60 (0.13–0.88)
0.56 (0.45–0.66) 0.183 0.76 (0.64–0.85) 0.076
0.47 (0.36–0.58) 0.53 (0.32–0.71)
0.61 (0.51–0.70) b0.001 0.78 (0.67–0.86) b0.001
0.31 (0.19–0.44) 0.43 (0.23–0.62)
0.61 (0.48–0.71) 0.024 0.79 (0.66–0.88) 0.041
0.46 (0.35–0.55) 0.57 (0.40–0.71)
0.60 (0.46–0.72) 0.116 0.78 (0.51–0.91) 0.318
0.48 (0.38–0.57) 0.68 (0.56–0.77)
0.43 (0.25–0.60) 0.218 1.00 (1.00–1.00) 0.008
0.54 (0.45–0.62) 0.64 (0.52–0.74)
0.57 (0.46–0.67) 0.204 0.75 (0.58–0.86) 0.147
0.46 (0.34–0.57) 0.65 (0.51–0.77)
0.58 (0.47–0.67) 0.097 0.78 (0.63–0.88) 0.015
0.43 (0.31–0.55) 0.60 (0.44–0.73)
0.67 (0.56–0.75) b0.001 0.89 (0.74–0.96) b0.001
0.28 (0.18–0.40) 0.57 (0.43–0.69)
855J. Li et al. / EBioMedicine 2 (2015) 851–8583.4. Validation the functional role of PA28γ both in vitro and in vivo
On the basis of the clinical ﬁndings described above, we evaluated
the effect of PA28γ on OSCC cell lines and xenograft models. We hy-
pothesized that PA28γmight act as a tumor promoter. If so, PA28γ si-
lencing should reverse some of the early processes of tumorigenesis.
PA28γ silencing in both OSCC cell lines caused decreased cell viability
and colony growth (Figs. S6, 4a). However, this silencing had no such ef-
fect on HOK cells. A signiﬁcant induction of apoptosis was observed
after treatment of cells with PA28γ-speciﬁc siRNA (Fig. 4b). Similar re-
sults were also observed in the TUNEL assay (Fig. S7). These results sug-
gest that PA28γ silencing can inhibit cell proliferation via induction of
apoptosis in OSCC cells. Moreover, our data suggested that PA28γ si-
lencing could inhibit the migration and invasion of OSCC cells in vitro
(Fig. S8).
We further investigated whether PA28γ silence could inhibit tumor
growth in vivo. OSCC cells treated with PA28γ siRNA modiﬁed with 2ʹ
OMe and 3ʹ Chol (PA28γ-si group) which have a high effective interfer-
ence (Fig. 4c), scramble siRNA (NS-si group) or PBS (CTRL group) were
transplanted subcutaneously on the right back of BALB/c nude mice.
Tumor growth in the PA28γ-si group was much slower than the other
two groups. There was a 40–50% reduction in the average tumor vol-
ume in the PA28γ-si group (Fig. 4d, e). To investigate the potential
mechanisms underlying the effects of PA28γ silencing in vivo, we
examined tumor cell proliferation, microvessel density (MVD)
(Rechsteiner and Hill, 2005), and tumor cell apoptosis. As shown in
Fig. S9, dramatic reductions in PCNA expression and tumor angiogene-
sis and signiﬁcant increases in TUNEL-positive nuclei were found in the
tumors in the PA28γ-si group compared with those in the other two
groups.Fig. 2. Overall Survival (OS) of OSCC patients with high and low expression of PA28γ in Three
(b) Overall Survival in CD-II cohort. (c) Overall Survival in CD-I and -II cohorts. (d) Overall Sur4. Discussion
In the current study, our results showed that the proteasomal activa-
tor PA28γ is a prognostic biomarker in OSCC with higher expression
levels correlating with worse outcomes compared with normal tissues.
We studied three cohorts from China and found consistent results
supporting a pronounced effect of PA28γ as a prognostic biomarker
with a total of 368 patients, whichwas conﬁrmed by an external valida-
tion cohort of 460 HNSCC patient specimens from the TCGA database.
The corresponding role of this gene in regulating tumorigenesis andme-
tastasis was also been evaluated.
PA28γ is a member of the PA28 protein family, which has been
shown to bind speciﬁcally to 20S proteasomes and stimulate the hydro-
lysis of peptides (Rechsteiner et al., 2000). The PA28γ–20S proteasome
pathway plays a very important role in cellular processes. Two recent
studies have indicated a role for PA28γ in the regulation of the cell
cycle and cell proliferation (Barton et al., 2004; Li et al., 2009). Some cel-
lular targets of PA28γ related to the regulation of cell apoptosis have
also been identiﬁed (He et al., 2012; Liu et al., 2010). PA28γ is
overexpressed in some types of cancers and has been linked with mul-
tiple cancer-related pathways (He et al., 2012). Our results indicated
that PA28γ may be a tumor promoter gene that can contribute to the
development of a more aggressive form of oral carcinoma. Its expres-
sion negatively correlates with patient survival. An auto-regulatory
feedback loop has recently been reported between p53 and PA28γ,
while a p53 mutation, which is themost comprehensive genomic char-
acterization of HNSCC (Cancer Genome Atlas N, 2015), could enhance
PA28γ transcription in some cancer cells (Ali et al., 2013). Therefore,
the prognostic signiﬁcance of PA28γ may be driven by p53 mutation;
this mechanism warrants further investigation.cohorts deﬁned by the Kaplan–Meier survival curves. (a) Overall Survival in CD-I cohort.
vival in GZ cohort.
Table 3
Multivariate analyses of survival among patients with oral squamous cell carcinoma.
Characteristic CD-I cohort (N = 118) CD-II cohort 2 (N = 156) CD cohort combined (N = 274) GZ cohort (N = 94)
OS at ﬁve years OS at ﬁve years OS at ﬁve years OS at ﬁve years
HR P Value⁎ HR P Value⁎ HR P Value⁎ HR P Value⁎
(95% CI) (95% CI) (95% CI) (95% CI)
Smoking history
Never Reference 0.072 Reference 0.979 Reference 0.180 Reference 0.349
Ever 1.87 (0.65–3.68) 1.01 (0.59–1.72) 1.32 (0.88–1.98) 1.45 (0.67–3.13)
Drinking history
Never Reference 0.717 Reference 0.023 Reference 0.065 Reference 0.103
Ever 1.14 (0.57–2.28) 1.86 (1.09–3.16) 1.47 (0.98–2.22) 1.89 (0.88–4.07)
Cell differentiation
High Reference 0.036 Reference 0.078 Reference 0.006 Reference 0.014
Moderate or Low 1.98 (1.05–3.75) 1.55 (0.95–2.50) 1.70 (1.16–2.48) 2.84 (1.23–6.52)
Tumor stage
T1 or T2 Reference 0.040 Reference 0.399 Reference 0.011 Reference 0.991
T3 or T4 2.20 (1.04–4.69) 1.23 (0.76–1.97) 1.65 (1.12–2.44) 1.01 (0.46–2.19)
Nodal stage
N0 Reference 0.316 Reference 0.012 Reference 0.016 Reference 0.016
N1-N3 1.40 (0.72–2.72) 1.89 (1.15–3.10) 1.62 (1.09–2.40) 2.61 (1.20–5.69)
Radiotherapy or chemotherapy
Yes Reference 0.004 Reference 0.141 Reference 0.001 Reference 0.051
No 2.47 (1.34–4.53) 1.44 (0.89–2.35) 1.82 (1.26–2.61) 2.17 (1.00–4.69)
PA28γ
Low expression Reference b0.001 Reference b0.001 Reference b0.001 Reference b0.001
High expression 5.14 (2.51–10.5) 2.82 (1.73–4.61) 3.02 (1.05–4.43) 6.39 (2.12–19.3)
Abbreviations: OS, Overall Survival; CD, Chengdu; GZ, Guangzhou; HR, Hazard Ratio.
⁎ P value was determined using Cox proportional-hazards model.
856 J. Li et al. / EBioMedicine 2 (2015) 851–858We explored the PA28γ mRNA (gene name: PSME3) expression
level in the head and neck cancer group from the TCGA database. Very
few genomic changes (2 cases of mutation and 1 case of ampliﬁcation
in 279 head and neck squamous cell carcinoma cases) were observed,
suggesting that the PA28γ contribution to oral cancer may not be
through genomic events, but more likely through some local condition
change events. This hypothesis is under further study in our laboratory.
To date, there has been no well-established predictive model for all-
cause death of patients with OSCC, or even head and neck cancer. In
this study, we generated a series of basicmodels that included four con-
ventional risk factors and one candidate biomarker, PA28γ. The inte-
grated discrimination improvement was estimated when PA28γ was
incorporated into different combinations of established risk factors in
Models 2, 3, and 4. The incorporation of PA28γ with established riskFig. 3. ROC curves for all-cause death of OSCC patients with or without PA28γ expression in th
(b) ROC curve for Model 3 in GZ cohort.factors improved the risk prediction for death, as shown by a substantial
increase in the C Statistic.We also used an alternativemodel by replace-
ment of tumor and nodal stage with clinical TNM stage in Model 3, as
the latter is a more commonly used clinical prognosis factor. Thus, the
role of each factor independently and in combination in predicting all-
cause death could be determined.Most importantly, thesemodels high-
light the prognostic value of PA28γ by itself or in combinationwith con-
ventional predictors. Our data were notable in that the replacement of
multiple clinical factors with a simpliﬁed alternative clinical factor
yields consistent results that would be extended to the clinical setting.
Furthermore, to evaluate themolecular basis for the clinical associa-
tion described above, we investigated the biologic role of PA28γ in can-
cer cell lines and OSCC xenograft models. Our study provided the ﬁrst
biological evidence for the role of PA28γ in tumor growth andree cohorts of two independent centers. (a) ROC curve for Model 3 in CD-I and -II Cohorts.
Fig. 4. Functional role of PA28γ on the tumor growth. (a) Colony formation assay. PA28γ silencing led to colony formation inhibition in two OSCC cell lines (HSC-3 and CAL-27), after
10 days transfection with siRNA. All data are presented as the mean ± SD of three independent experiments (*P b 0.05). (b) PA28γ silencing induced the apoptosis in OSCC cells, deter-
mined by Flow Cytometry assay, after 48 h transfection with siRNA. All data are presented as the mean ± SD of three independent experiments (*P b 0.05). (c) Chemically-modiﬁed
PA28γ-si could inhibit PA28γ gene expression in HSC-3, illustrated by qPCR, 48 h. All data are presented as the mean ± SD of three independent experiments (*P b 0.05) (d ande) The
tumor volumes (mean ± SD) of PA28γ-si group were signiﬁcantly smaller compared to the other two groups, 30 days after injecting transfected cells. (n = 5, *P b 0.05).
857J. Li et al. / EBioMedicine 2 (2015) 851–858metastasis. Beyond its signiﬁcance in metastasis-related outcome pre-
diction, our data also showed that PA28γ silencing signiﬁcantly sup-
pressed tumor angiogenesis. Further studies are in progress in our
laboratory.
The clinically signiﬁcant role of PA28γ expression as a surrogate
marker in OSCC is clearly established in this study. However, our
model does have some limitations. Some reports have described prog-
nosis according to a primary sub-site, which differs in HNSCC (Chung
et al., 2014), themain primary sites of patients with OSCC in our cohorts
were ventral tongue or ﬂoor of mouth. Although there is no difference
between sub-sites in our cohorts, we could not examine survival out-
comes based on PA28γ status and primary site, given the limited num-
ber of subset cases. Therefore, our data show that the use of PA28γ as a
prognostic biomarker in OSCC requiresmore investigation before broad
application in the clinical setting.
5. Conclusion
Overall, we found that PA28γ is a good predictor of the risk of death
in OSCC and adds additional information to well-established prognostic
factors, which were derived from OS and DFS analyses as well as the
eventual four statistic models in those cohorts. Meanwhile, the
functional studies in vitro and in vivo in a mouse xenograft model also
validated the cellular effects of PA28γ in OSCC. However, the molecular
mechanisms responsible for its function are still unclear. The identiﬁca-
tion of the targets and action model of PA28γ in OSCC needs to be
further delineated in our further study.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.07.004.
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